Innovation Pharmaceuticals Inc (IPIX)

[a1derfullife]

Gilead buys YM-bio for $510 million

YM-bio has a drug that had good results in a phase I/II trial treating a rare cancer called myelofibrosis. There are ~ 30,000 people in the US with this condition, and another ~ 140,000 with related conditions.

If Kevetrin works, it has the potential to treat ~ 10 million people.

So what could Kevetrin be worth?

A quick calculation: $510 million * (10 million)/170,000) = $30 billion.

Works for me

A1



Gilead buyout

YMI Bio website

Estimate of prevalence of myelofibrosis and related conditions